ABSTRACT-The antinephritic effect of DP-1904 [6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid hydrochloride], a thromboxane (TX) A2 synthase inhibitor, was compared with that of OKY-046 and azathioprine, using an experimental model of nephritis, crescentic-type anti-glomerular basement membrane (GBM) nephritis. Test drugs were given p.o. once daily from an autologous phase in which proteinuria was already fully developed. DP-1904 (15 and 45 mg/kg per day) and OKY-046 (20 mg/kg per day), another TXA2 synthase inhibitor, significantly inhibited the development of glomerular alteration as well as the elevation of proteinuria. On the other hand, azathioprine (20 mg/kg per day), an immunosuppressive agent, failed to suppress the proteinuria. A single administration of DP-1904 or OKY-046 inhibited glomerular TXB2 production and increased glomerular prostaglandin (PG) E2 and 6-keto PGFIa, production in nephritic rats. Both drugs apparently decreased the depositions of both rabbit immunoglobulin (Ig) G and rat IgG on GBM in nephritic rats, but azathioprine inhibited only the deposition of rat IgG. These results suggest that DP-1904 may be an effective agent for the treatment of proliferative glomerulonephritis and its antinephritic effect may be due to the amelioration of abnormal metabolism of arachidonic acid.
Recently, it has been demonstrated in experimental animal models that induction of immunological glomerular injury is associated with an increase in production of prostaglandins and thromboxane synthesis in isolated glomeruli (1) (2) (3) and renal cortex (4) . It had been believed that thromboxane (TX) A2 mediates the deterioration of renal function due to its vasoconstrictive, platelet pro-aggregatory and chemotactic actions (5), while prostaglandins such as prostaglandin (PG) E2 and PGI2 improve renal function due to their vasodilator and antiplatelet actions. On the basis of these findings, we have already investigated the antinephritic effect of DP-1904 [6-(1-imidazolylmethyl)-5, 6, 7, 8-tetrahydronaphthalene-2-carboxylic acid hydrochloride], a new TXA2 synthase inhibitor ( Fig. 1) , given from the heterologous phase (the day of injection of the antiserum against glomerular basement membrane (GBM)) to rats with crescentic type anti-GBM nephritis, which resembles rapidly progressive glomerulonephritis in humans. The beneficial effect of DP-1904 found in such experiments may be due to the inhibition of platelet aggregability and the restoration of decreased renal tissue blood flow (6) . However, in the clinical situation, therapy for glomerulonephritis is started from the establishment of nephritic symptoms. Therefore, in the present study, we compared the antinephritic effect of DP-1904 administered from the autologous phase of crescentic-type anti-GBM nephritis in rats with those of OKY-046 and azathioprine. Fig. 1 .
Chemical structure of DP-1904.
Animals
Male Sprague-Dawley strain SPF rats (Nihon SLC, Shizuoka), weighing approximately 160g, were used in the experiment. These animals were housed in an air-conditioned room at 22±2 C during the experimental period.
Drugs
DP-1904 and OKY-046 were kindly provided from Daiichi Pharmaceutical
Co. (Tokyo) and Kissei Pharmaceutical Co. (Nagano), respectively. Azathioprine was purchased from Sigma Chemical Co. (St. Louis, MO, USA). DP-1904 and OKY-046 were dissolved in distilled water, and azathioprine was suspended in 1 % gum arabic.
3. Experimental protocols 3.1. Protocol for evaluation of antinephritic effect of DP-1904: Crescentic-type anti-GBM nephritis was induced in rats by injecting 6.5 mg rabbit gamma-globulin in 0.25 ml of Freund complete adjuvant into the hind foot pads, following the injection of 0.6 ml of rabbit anti-rat GBM serum into the tail vein, in accordance with the method reported previously (7) . On the 20th day after the anti-GBM serum injection, urine samples were collected for 24 hr. The animals were then divided into 5 groups (n=8), so that the average protein content in the 24-hr urine samples of each group was at a similar level. Each of the five groups was given 5, 15 or 45 mg/kg of DP-1904 (anti-GBM+DP-1904), 20 mg/kg of OKY-046 (anti-GBM + OKY-046) or 20 mg/kg of azathioprine (antiGBM+azathioprine) in a volume of 1 ml per 100 g of body weight, orally, daily from the 21st day after the anti-GBM serum injection to the 51st day. The remaining group was given orally distilled water instead of test drugs and served as the anti-GBM nephritic group (anti-GBM). In addition, a control group (n = 8) that did not receive the anti-GBM serum was used for comparison with the nephritic group.
3.2. Protocol for evaluation of antinephritic mechanisms of DP-1904: Crescentic-type anti-GBM nephritis was induced by the same method as indicated in section 3.1.
To investigate the effect of a single p.o. administration of test drugs on glomerular TXB2 (the stable metabolite of TXA2), PGE2 and 6-keto PGFIa (the stable metabolite of PGI2) production on the 21st and 51st days, we used 7 groups of 4 rats each: control group, anti-GBM nephritic group, anti-GBM + DP-1904 group ( 5. Measurement of urinary protein, plasma creatinine and antibody titer The urinary protein content was determined by the method of Kingsbury et al. (8) and expressed as mg/24-hr urine. The plasma creatinine content was determined with a commercial assay kit (CRE-EN; Kainos, Inc., Tokyo) and expressed as mg/dl per 100 g body weight. The plasma antibody titer against rabbit gamma-globulin was determined by indirect hemagglutination using sensitized sheep red blood cells (9) and expressed as the loge of the hemagglutination titer.
Assessment of histopathological parameters
in the glomeruli For light microscopic study, the kidneys were fixed in alcohol, and the tissues embedded in paraffin were then cut into 2-to 3-tm thick sections. The sections were stained with hematoxylin and eosin or Masson's trichrome. To assess the glomerular hypercellularity, the number of nuclei was counted and expressed as the number per equatorial cross section in ten glomeruli per animal. Crescent formation, adhesion of Bowman's capsule to capillary walls (adhesion) and fibrinoid necrosis in the glomeruli were evaluated by a different person who did not know the identify of the sections. For assessing each of the histopathological parameters, the degrees of crescent formation, adhesion and fibrinoid necrosis were scored as 1 (mild), 2 (moderate) and 3 (severe) (10) . The number of the glomeruli corresponding to each score is shown as nl, n2 and n3. A crescent formation index (CI), an adhesion index (AI) and a fibrinoid necrosis index (FI) were calculated from the following formula:
CI, AI and FI = 1 x n1+2 x n2+3 x n3. The index of glomerular lesions (IGL) was calculated for evaluating the degree of glomerular lesions as follows:
We gave 3, 2 and 1 points to CI, Al and FI, respectively, because we consider that CI, Al and FI are associated with the glomerular lesion in this order; and the "50" shows the number of glomeruli.
Immunoperoxidase studies An indirect immunoperoxidase
technique employing avidin-biotin peroxidase kits (Vecta Stain ABC Kit; Vector Institution, Burlingam, CA, USA) was used throughout the study (11) . In brief, the paraffin sections, prepared by the same method as described in section 3.1., were subsequently incubated with 1-to 5-fold diluted normal rabbit serum, an appropriate dilution of the individual mouse monoclonal antibody for rabbit immunoglobulin (Ig) G or rat IgG (Cappel Laboratories, Inc., West Chester, PA, USA), affinity-purified rabbit anti-mouse peroxidase conjugated immunoglobulin also at the appropriate dilution, and finally with diamino-benzidine tetrahydrochloride (0.5 mg/ml in PBS plus 0.0101o H202) for 3 -5 min. Under a light microscope, we selected the glomeruli that were equatorially sectioned and had the vascular pole.
The intraglomerular rabbit IgG or rat IgG depositions were measured by an image-analyzer (Imageanalyzer VI; Toyobo, Tokyo) and expressed as x 10-3 mm3/glomerular cross section (GCS).
Effects of a single administration
of DP-1904 on glomerular TXB2, PGE2 and 6-keto PGFIa production in nephritic rats The glomeruli were isolated by the differential sieving technique of Zoja et al. (12) from kidneys perfused with Krebs-Ringer phosphate-buffered saline (pH 7.2) obtained from the normal and nephritic rats that were treated as described in section 3.2. The isolated glomeruli (the purity was more than 80010 when observed under a light microscope) were then incubated in Krebs-Ringer phosphate-buffered saline at 37C for 30 min. The incubation mixture was then centrifuged, and the supernatant was frozen at -70'C for the determination of TXB2, PGE2 and 6-keto PGF1a. The amounts of TXB2, PGE2 and 6-keto PGF1a in the glomeruli were determined by radioimmunoassay (New England Nuclear, Boston MA, USA). The protein content in the glomeruli was assayed by a colorimetric method (Bio-Rad, Richmond, CA, USA).
Statistical analyses
The 1. Antinephritic effects of DP-1904 on crescentic-type anti-GBM nephritis 1.1. Urinary protein excretion and plasma creatinine content ( Fig. 2) : When test drugs were given from the 21st day after the anti-GBM serum, DP-1904 at 15 and 45 mg/kg significantly suppressed the urinary protein excretion by 45010 and 54010, respectively, through the 31st to 50th days. In addition, by the 51st day, this agent at the 2 doses mentioned had inhibited the increase of plasma creatinine content returning it to almost the normal level. OKY-046 at 20 mg/kg also inhibited the urinary protein excretion by 35%, and the plasma creatinine content was almost at the normal level on the 51st day. On the other hand, azathioprine at 20 mg/kg showed only a tendency to diminish both the urinary protein excretion and the plasma creatinine content. (Table 1 ). In addition, DP-1904 at the 3 doses reduced the IGL by 48% to 74% at the 51st day (Fig. 3) . OKY-046 (20 mg/kg) also reduced it by 50%. On the other hand, azathioprine (20 mg/kg) slightly reduced it by 20% at the 51st day. Representative micrographs of the glomeruli from drug-treated and untreated anti-GBM nephritic rats are given in Fig. 4. 1.3. Effects on plasma antibody titer against rabbit gamma-globulin: At the 51st day, the elevation of the antibody titer due to nephritis was significantly inhibited by DP-1904 (15 and 45 mg/kg) (P <0.05 vs anti-GBM). Test dugs were given p.o., daily to rats from the 21st day after injection of anti-GBM serum to the 51st day; and both kidneys were taken on the 51st day for light microscopic study. Values indicate the means ±S.D., and N indicates the number of rats used. GCS stands for glomerular cross-section. a indicates a significant difference from the control at p<0.01; b indicates a significant difference from the anti-GBM at P<0.05. (Fig. 6 ): The effects of DP-1904 and OKY-046 on glomerular TXB2, PGE2 and 6-keto PGFIa production were examined at 4 hr after the single p.o. administration of test drugs to nephritic rats on the 21st and 51st days after anti-GBM serum injection. Glomerular TXB2 production in the anti-GBM group was 2.5-fold higher than that of the control group at the 21st and 51st days. On the other hand, the levels of glomerular PGE2 and 6-keto PGFIa production were similar between the anti-GBM nephritic animals and the control animals. At 4 hr after drug treatment, DP-1904 at 5, 15 and 45 mg/kg dose-dependently inhibited the increment of glomerular TXB2 production by 23% to 85% at the 21st and 51st days. In addition, DP-1904 at 5, 15 and 45 mg/kg caused increases by 15010 to 2701o, in PGE2 and increases by 21010 to 45%, in 6-keto PGFIa. OKY-046 (20 mg/kg) also decreased TXB2 production by 36010 to 39010, while it resulted in an increase of 12010, in PGE2 and an increase of 26010 in 6-keto PGFIa at the 51st day. On the other hand, azathioprine (20 mg/kg) had no effects on glomerular PGs production.
The glomerular injury of anti-GBM nephritis in rats has been demonstrated to consist of a heterologous phase and an autologous phase. Immediately after the injection of anti-GBM serum (rabbit anti-GBM antibody, heteroantibody), the heterologous phase is caused by the binding of the injected rabbit anti-GBM antibody to the glomeruli followed by the activation of complement. Following this, 7 to 10 days later, the autologous phase is instarted drug administration from the autologous phase. The effects of DP-1904 on anti-GBM nephritis were more potent than those of OKY-046. Recently, it has been reported that glomerular synthesis and/or urinary excretion of vasoconstrictive TXA2 and vasodilator PGE2 are significantly increased in various experimental models of renal diseases such as anti-GBM nephritis (1, 3, 13, 14) , passive Heymann nephritis (15) , adriamycin nephrosis (16), cyclosprin A nephrotoxicity (17) and murine lupus nephritis (4). Furthermore, Lianos et al. reported that in anti-GBM nephritic rats, the increased glomerular TXA2 synthesis correlates positively with the extent of proteinuria and negatively with the decrease in glomerular filtration rate (1) . The origin of increased TXA2 synthesis is uncertain. In anti-GBM nephritis, the heterologous phase is characterized by intraglomerular activation of complement and platelets and infiltration of neutrophils, while the autologous phase is characterized by infiltration of macrophages/monocytes and proliferation of mesangial cells (18) . In a platelet depletion study, Wu et al. demonstrated that platelets and neutrophils are critical to the imbalanced glomerular arachidonate metabolism, especially TXA2 and leukotriene B4, in the heterologous phase of anti-GBM nephritis (19) . Mesangial cells in culture may be induced to release prostanoids by a variety of cytokines (20) (21) (22) . Additionally, interleukin (IL)-1 and tumor necrosis factor (TNF)-a induced an increase in cyclooxygenase activity and protein mass in mesangial cells (23) . Martin et al. recently demonstrated that IL-1 enhanced the expression of cyclooxygenase 2 mRNA and protein synthesis in mesangial cells (24) . Therefore, it is considered in the cases of crescentic-type anti-GBM nephritis that the origin of increased synthesis of TXA2 in the heterologous phase may be mainly neutrophils and platelets, while that in the autologous phase may originate from mainly macrophages/monocytes and the mesangial cells.
When the effects of a single administration of DP-1904 or OKY-046 on the synthesis of glomerular prostanoids were examined using the isolated glomeruli that had been under nephritic conditions, glomerular PGE2 and 6-keto PGF,a productions were similarly increased by both drugs. Accordingly, it is suggested that the antinephritic effect of DP-1904 and OKY-046 may be attributed to the suppression of excessive glomerular TXA2 synthesis or the increase in the ratio of PGE2 and PGI2 to TXA2 produced by both drugs in the autologous phase as well as in the heterologous phase (6) . Although the precise mechanism by which DP-1904 and OKY-046 increase the PGE2 and PGI2 production remains unclear, it seems reasonable to consider that the inhibition by TXA2 synthetase inhibitors of TXA2 synthesis in arachidonic metabolism promotes the transformation of PG endoperoxides (PGG2 and PGH2) to PGE2 and PGI2. This observation illustrates the more potent effect of DP-1904 in comparison to OKY-046. In the present experiment, DP-1904 and OKY-046 apparently reduced the depositions of both rabbit IgG and rat IgG on GBM of anti-GBM nephritic rats. On the other hand, azathioprine markedly inhibited the antibody titer and reduced only the deposition of rat IgG. The decrease in glomerular rabbit IgG deposition by DP-1904 and OKY-046 may be due to the elevation in the ability of both drugs to eliminate glomerular fixed hetero-antibody.
Regarding these results, we demonstrated that TXA synthetase inhibitors were able to elevate eliminating heterosubstances in the glomeruli (unpublished data). Furthermore, the reduction of antibody titer by a long-term administration of DP-1904 may be partially due to the increase of the immunosuppressive eicosanoid PGE2. PGE2 has been shown to down-regulate T lymphocyte function (25) likely through its ability to decrease IL-1 and IL-2 production (26) and its capacity to decrease class II expression on antigen-presenting cells such as macrophages (27) . Moreover, PGE2 has also been demonstrated to possess, in addition to immunosuppressive effects, the capacity to enhance certain aspects of the immune response such as IgG, and IgE production (28). Hattori et al. reported that azathioprine administered from the heterologous phase had a antinephritic effect on rat crescentic-type anti-GBM nephritis (29) . In the present study, DP-1904 and OKY-046, TXA2 synthase inhibitors, administered from the autologous phase was effective against proteinuria, but azathioprine was not. Azathioprine apparently reduced the deposition of rat IgG in the glomeruli according to the suppression of auto-antibody formation. Azathioprine had no effects on glomerular PGs production and glomerular rabbit IgG deposition, although TXA2 synthase inhibitors increased glomerular PGE2 and PGI2 synthesis and diminished glomerular rabbit IgG deposition. These results suggest that, because TXA2 synthase inhibitors inhibit platelet aggregability and can restore decreased renal tissue blood flow by ameliorating the abnormal production of arachidonic acid metabolites (6) in addition to the decreasing effect of glomerular rabbit IgG; These data establish that TXA2 synthase inhibitors may be more useful than immunosuppressive agents such as azathioprine for the treatment of glomerulonephritis.
DP-1904 administered from the autologous phase has a more potent antinephritic action than OKY-046 on rat crescentic-type anti-GBM nephritis. OKY-046 has been reported to be clinically effective for the treatment of chronic glomerulonephritis accompanied by a nephrotic syndrome (30) . Therefore, DP-1904 is expected to have a clinical effect on this type of chronic glomerulonephritis.
